Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 17  |  Issue : 5  |  Page : 1209--1218

Association of miR-155 and MIR155HG polymorphisms with cancer risk: A meta-analysis


Zhishan Zou1, Hui Lu1, Wenliang Zhang2, Yiming Li1, Yi He1, Huancai Lin1, Wei Zhao1, Dongsheng Yu1, Binghui Zeng1 
1 Guanghua School of Stomatology, Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, Guangzhou, China
2 Department of Pediatrics, The University of Hong Kong-Shenzhen Hospital, Shenzhen; Center for High Performance Computing, Joint Engineering Research Center for Health Big Data Intelligent Analysis Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China

Correspondence Address:
Binghui Zeng
Guanghua School of Stomatology, Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, Guangzhou, 510055
China
Dongsheng Yu
Guanghua School of Stomatology, Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, 510055
China

Background: Analysis of emerging data shows that miRNAs, including miR-155, play important roles in tumorigenesis. Several studies have indicated that miR-155 and MIR155HG polymorphisms may be related to cancer risk, but the association was controversial. Therefore, we conducted this first-reported comprehensive meta-analysis of the association of miR-155 and MIR155HG polymorphisms with cancer risk. Materials and Methods: We searched several databases, including PubMed, Embase, and Web of Science, to identify the eligible studies reporting the association of miR-155 and MIR155HG polymorphisms with cancer risk. We calculated the pooled odds ratios (ORs) and 95% confidence intervals (CIs) to analyze the association. Stata software (version 16.0) was used to analyze the data we collected. Results: After being carefully and strictly screened, eight articles reporting on six common single-nucleotide polymorphisms consisting of 6184 cases and 6896 controls were included in this meta-analysis. The six polymorphisms included were rs767649 (T>A), rs928883 (A>G), rs2829803 (G>A), rs1893650 (T>C), rs4143370 (G>C), and rs12482371 (T>C). Our results showed that, in the overall analysis, heterozygotes increased cancer risk, with a marginal P value, compared with wild-type (OR = 1.06, 95% CI = 1.00–1.12, P = 0.062). Subsequent analyses showed that only rs767649 was associated with an increased risk of non-small-cell lung cancer (NSCLC) in an allele model (T vs. A: OR = 1.15, 95% CI = 1.04–1.26, P = 0.007), a homozygote model (TT vs. AA: OR = 1.31, 95% CI = 1.06–1.60, P = 0.011), and a recessive model (TT vs. AT + AA: OR = 1.30, 95% CI = 1.08–1.55, P = 0.005). Conclusion: The present meta-analysis indicates that the rs767649 polymorphism might be a potential factor for NSCLC risk; however, more studies should be conducted to confirm these findings.


How to cite this article:
Zou Z, Lu H, Zhang W, Li Y, He Y, Lin H, Zhao W, Yu D, Zeng B. Association of miR-155 and MIR155HG polymorphisms with cancer risk: A meta-analysis.J Can Res Ther 2021;17:1209-1218


How to cite this URL:
Zou Z, Lu H, Zhang W, Li Y, He Y, Lin H, Zhao W, Yu D, Zeng B. Association of miR-155 and MIR155HG polymorphisms with cancer risk: A meta-analysis. J Can Res Ther [serial online] 2021 [cited 2022 May 16 ];17:1209-1218
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=5;spage=1209;epage=1218;aulast=Zou;type=0